Wissenschaftliche Arbeiten

Karlhofer FM and WM Yokoyama: Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen. IL-2 activated NK cells possess additional stimulation pathways. J. Immunol. 146:3662, 1991

Karlhofer FM, RK Ribaudo and WM Yokoyama: MHC class I alloantigen specificity of Ly-49+ IL-2 activated natural killer cells. Nature 358:66, 1992

Karlhofer FM, RK Ribaudo and WM Yokoyama: The interaction of Ly-49 with H-2Dd globally inactivates natural killer cell cytolytic activity. Trans. Assoc. Am. Phys. 105:72, 1992

Sykes M, MW Harty, FM Karlhofer, DA Pearson, G Szot, WM Yokoyama: Hematopoietic cells and radioresistant host elements influence natural killer cell differentiation. J. Exp. Med. 178:223, 1993

Daniels BF, FM Karlhofer, WE Seaman and WM Yokoyama: A natural killer cell receptor specific for a major histocompatibility complex class I molecule. J. Exp. Med. 180:687, 1994

Smith HRC, FM Karlhofer and WM Yokoyama: Ly-49 multigene family expressed by IL-2 activated NK cells. J. Immunol. 153: 1068, 1994

Karlhofer FM, R Hunziker, A Reichlin, DH Margulies and WM Yokoyama: Host MHC class I molecules modulate in vivo expression of a natural killer cell receptor. J. Immunol. 153:2407, 1994

Yokoyama WM, HRC Smith, FM Karlhofer: The Ly-49 family of putative NK-cell receptors specific for target cell MHC class I molecules. In: MHC antigens and NK cells. pp 68-91; Eds.: R Solana, J Pena, CRC press, Boca Raton, FL, 1994. (Buchkapitel)

Karlhofer FM, MM Orihuela and WM Yokoyama: Ly-49 independent NK cell specificity revealed by NK cell clones derived from p53-deficient mice. J. Exp. Med. 181:1785, 1995

Kunstfeld R, R Kirnbauer, G Stingl, and FM Karlhofer: Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch. of Dermatol. 139:850, 2003

Wöhrl S, FM Karlhofer, K Derfler, D Zillikens, G Stingl and A Geusau: Pemphigoid gestationis: Treatment with immunoapheresis. JDDG 2:126, 2003

Karlhofer FM, T Hashimoto, K Slupetzky, M Kiss, Y Liu, M Amagai, F Pieczkowski, D Födinger, R Kirnbauer and G Stingl: 230 kDa and 190 kDa proteins in addition to desmoglein 1 as immunological targets in a subset of pemphigus foliaceus with a combined cell surface and basement membrane zone immune staining pattern. Exp. Dermatol. 12:646-654, 2003

Cauza K, G Hinterhuber, B Sternicky, K Brugger F Karlhofer, K Wolff and D Foedinger: Unususal clinical manifestation of linear IgA dermatosis. J Am. Acad. Derm.51:(2Sup):S112, 2004

Successful use of acitretin in combination with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis von Zumbusch type. Kopp T, F Karlhofer, Z Szepfalusi , A Schneberger, G Stingl, A Tanew:  Br J Dermatol 151:912, 2004

Transglutaminases as diagnostically relevant autoantigens in patients with gluten sensitivity.
Heil PM, B Volc-Platzer, FM Karlhofer, W Gebhart, WD Huber, T Benesch, H Vogelsang, G Stingl. JDDG 2005 3(12):974-8

Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, Bartel G, Krober SM, Greinix H, Rosenmaier A, Karlhofer F, Wick N, Mazal PR. Nature Med. 2006 Feb:12(2):230-4

IgA pemphigus- occurrence of anti-desmocollin-1 and anti-desmoglein-1 antibody reactivity in an individual patient. Kopp T, C Sitaru, F Pieczkowski, A Schneeberger, D Födinger, D Zillikens, G Stingl and FM Karlhofer. JDDG 2006 4(12):1045-50

Successful treatment of patients with severe secundary Raynaud´s phenomenon with the endothelin receptor antagonist bosentan. Selenko-Gebauer N, N Duschek, G Minimair, G Stingl and FM Karlhofer. Rheumatology (Oxford) 2006 45 Suppl 3:iii45-iii48

Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas. Stur K, FM Karlhofer, G Stingl. JID 2006 127:802-807

MHC Class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66-70,1992. J Immunol 2006 177(9):5761-5

Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases . Zillikens D, K Derfler, R Eming, G Fierlbeck, M Goebeler, M Hertl, SC Hofmann, F Karlhofer, O Kautz, M Nitschke, A Opitz, S Quist, C Rose,S Schanz, E Schmidt, I Shimanovich, M Sticherling, F Ziller. JDDG 2007 5:881-887

Efalizumab in routine use: a clinical experience. Selenko-Gebauer N, FM Karlhofer, G. Stingl. Br J Dermatol. 2007 156 Suppl 2:1-6

Recommendations for the use of rituximab (anti-CD20 andtibody) in the treatment of autoimmune bullous skin diseases. Hertl M, D Zillikens, L Borradori, L Bruckner-Tuderman, H Burckhard, R Eming, A Engert, M Goebeler, S Hofmann, N Hunzelmann, F Karlhofer, O Kautz, U Lippert, A Niedermeier, M Nitschke, M Pfütze, M Reiser, C Rose, E Schmidt, I Shimanovich, M Sticherling, S Wolff-Franke. JDDG 2008 6:366-373

Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Jimenez-Boj E, N Kedersha, M Tohidast-Akrad, FM Karlhofer, G Stummvoll, C Zimmermann, W Ulrich, S Guiducci, E Hoefeler, M Aringer, G Schett, M Matucci-Cerinic, JS Smolen, G Steiner. Arthritis Rheum. 2008 58:1226-1236

Fatal paraneoplastic pemphigus associated with a mediastinal tumor. Pfistershammer K, G Minimair, D Foedinger, M Czerny, C Zauner, F Pieczkowski, G Stingl, FM Karlhofer. JDDG 2008 6:

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. Jalili A, A Pinc, F Pieczkowski, F Karlhofer, G Stingl, SN Wagner. JDDG 2008 6:1066-1069

De novo tuberculosis during infliximab therapy in a patient with Behçet disease. Skvara H, Duschek N, Karlhofer F. J Dtsch Dermatol Ges. 2009 Jul;7(7):616-9. Epub 2009 Feb 2. English, German. PMID: 19192011

T cells co-producing Mycobacterium tuberculosis-specific type 1 cytokines for the diagnosis of latent tuberculosis. Nemeth J, Winkler HM, Karlhofer F, Selenko-Gebauer N, Graninger W, Winkler S. Eur Cytokine Netw. 2010 Mar;21(1):34-9. PMID: 20146988